Semaglutide Pathway vs Lipo-B Pathway
Semaglutide drives appetite, satiety, and glucose-axis change — producing significant weight loss in candidates. Lipo-B is a lipotropic and B-vitamin support protocol — metabolic and energy support, not a weight-loss therapy. They occupy different roles and frequently stack.
Semaglutide pathway is decisive when meaningful weight loss is the primary endpoint and candidacy review supports GLP-1 therapy.
Lipo-B pathway is decisive for metabolic and energy support and frequently stacks with GLP-1 therapy.
Explore pathwayEducational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Is Lipo-B a substitute for GLP-1?
No — Lipo-B is adjunctive metabolic support, not a weight-loss therapy on its own.
Can they be combined?
Yes — provider-reviewed stacks are common.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment